“46% pretty much means every other patient who was getting IV opioids was having some sort of a respiratory depression event”
After a quick round up of COVID news in the contributor’s respective areas this piece gets involved in a much needed discussion about the “PRediction of Opioid-induced Respiratory Depression In Patients Monitored by capnoGraphY (PRODIGY)” trial.
PRODIGY trial is here:
Presented by Desiree Chappell and Monty Mythen with Mike Grocott, and their guests Ashish Khanna, Associate Professor, Section Head for Research, Department of Anesthesiology, Section on Critical Care Medicine, Wake Forest School of Medicine and Roop Kaw, Associate Professor of Medicine at Cleveland Clinic, Founder Member of The Society of Anesthesia and Sleep Medicine.
As mentioned TopMedTalk have been eagerly following the development of this research, you might also enjoy this piece we did here:
More discussion regarding risk factors for opioid-induced respiratory depression in surgical patients here: